Cardiovascular Effect of Incretin-Based Therapy in Patients with Type 2 Diabetes Mellitus: Systematic Review and Meta-Analysis.

PLoS One · 2016 · PMC4831684 · PMID 27078018

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

borderline significanceno p-value reported

However, vildagliptin was suggested to have a lower risk of CV disease with borderline significance (OR 0.82, 95% CI 0.68 to 0.99), which is consistent with the results from pooled data of 25 phase 3 trials assessing cardio-cerebrovascular safety of vildagliptin [ 26 ].

also in 7,017 other papers

showed a trendno p-value reported

Overall, incretin-based therapies showed a trend towards lower risk of cardiovascular disease compared to placebo or other antihyperglycemic agents, although the difference was not statistically significant.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.